K-ras Mutations in Sporadic Colorectal Tumors in Israel: Unusual High Frequency of Codon 13 Mutations and Evidence for Nonhomogeneous Representation of Mutation Subtypes
Overview
Affiliations
Colorectal cancer is one of the most common malignancies in the western world, including Israel. An important step in progression includes induction of activating mutations in the protooncogene K-ras. This event is very frequent and is detected in about 40% of colorectal carcinomas. Previous studies of a variety of genetic disorders revealed unique gene mutation prevalence in Jewish populations, attributed both to differences in genetic background and to variability in environmental exposure. To determine the incidence and molecular subtypes of K-ras mutations in colorectal cancer in Israel, compared with other countries, DNA was isolated from a random collection of 105 colorectal carcinoma samples, and K-ras mutations were detected by an improved designed RFLP and direct sequencing. K-ras sporadic mutations in colorectal cancer in Israel are relatively frequent, with a higher fraction in codon 13 than reported thus far. Comparison with other countries shows a vast heterogeneity in terms of the relative abundance of the affected K-ras codon and in type and representation of specific mutations. The heterogeneous distribution found may be due to a variable genetic background and different environmental factors involved in the initiation and propagation of sporadic colorectal cancer.
Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review.
Benmokhtar S, Laraqui A, Hilali F, Bajjou T, El Zaitouni S, Jafari M Clin Med Insights Oncol. 2024; 18:11795549241255651.
PMID: 38798959 PMC: 11128178. DOI: 10.1177/11795549241255651.
He J, Wu F, Han Z, Hu M, Lin W, Li Y Front Oncol. 2021; 11:632834.
PMID: 33996548 PMC: 8118670. DOI: 10.3389/fonc.2021.632834.
Tong G, Zhang G, Liu J, Zheng Z, Chen Y, Niu P Oncol Rep. 2020; 43(4):1187-1198.
PMID: 32323802 PMC: 7058009. DOI: 10.3892/or.2020.7511.
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.
Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi M Int J Mol Sci. 2017; 18(1).
PMID: 28106826 PMC: 5297828. DOI: 10.3390/ijms18010197.
Colorectal Cancer Biomarkers: Where Are We Now?.
Gonzalez-Pons M, Cruz-Correa M Biomed Res Int. 2015; 2015:149014.
PMID: 26106599 PMC: 4461726. DOI: 10.1155/2015/149014.